234 related articles for article (PubMed ID: 19234150)
21. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
Parrino J; McCurdy LH; Larkin BD; Gordon IJ; Rucker SE; Enama ME; Koup RA; Roederer M; Bailer RT; Moodie Z; Gu L; Yan L; Graham BS;
Vaccine; 2007 Feb; 25(8):1513-25. PubMed ID: 17126963
[TBL] [Abstract][Full Text] [Related]
22. Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene.
Laassri M; Meseda CA; Williams O; Merchlinsky M; Weir JP; Chumakov K
J Med Virol; 2007 Jun; 79(6):791-802. PubMed ID: 17457926
[TBL] [Abstract][Full Text] [Related]
23. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
McCurdy LH; Larkin BD; Martin JE; Graham BS
Clin Infect Dis; 2004 Jun; 38(12):1749-53. PubMed ID: 15227622
[TBL] [Abstract][Full Text] [Related]
24. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
Stittelaar KJ; van Amerongen G; Kondova I; Kuiken T; van Lavieren RF; Pistoor FH; Niesters HG; van Doornum G; van der Zeijst BA; Mateo L; Chaplin PJ; Osterhaus AD
J Virol; 2005 Jun; 79(12):7845-51. PubMed ID: 15919938
[TBL] [Abstract][Full Text] [Related]
25. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.
Perera LP; Waldmann TA; Mosca JD; Baldwin N; Berzofsky JA; Oh S
J Virol; 2007 Aug; 81(16):8774-83. PubMed ID: 17553867
[TBL] [Abstract][Full Text] [Related]
26. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine.
Ferrier-Rembert A; Drillien R; Tournier JN; Garin D; Crance JM
Vaccine; 2008 Mar; 26(14):1794-804. PubMed ID: 18336966
[TBL] [Abstract][Full Text] [Related]
27. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
Golden JW; Josleyn MD; Hooper JW
Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
[TBL] [Abstract][Full Text] [Related]
28. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.
Empig C; Kenner JR; Perret-Gentil M; Youree BE; Bell E; Chen A; Gurwith M; Higgins K; Lock M; Rice AD; Schriewer J; Sinangil F; White E; Buller RM; Dermody TS; Isaacs SN; Moyer RW
Vaccine; 2006 Apr; 24(17):3686-94. PubMed ID: 16430997
[TBL] [Abstract][Full Text] [Related]
29. [Laboratory markers of vaccinia virus in the vaccinia pulp, glycerinated vaccine and lyophilized suspension stored for 1 to 8 years at -25 degrees C].
Mihancea N
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1981; 26(3):191-7. PubMed ID: 7330566
[No Abstract] [Full Text] [Related]
30. A single vaccination with non-replicating MVA at birth induces both immediate and long-term protective immune responses.
Cheminay C; Körner J; Bernig C; Brückel M; Feigl M; Schletz M; Suter M; Chaplin P; Volkmann A
Vaccine; 2018 Apr; 36(18):2427-2434. PubMed ID: 29599088
[TBL] [Abstract][Full Text] [Related]
31. Mucosal administration of completely non-replicative vaccinia virus recombinant Dairen I strain elicits effective mucosal and systemic immunity.
Yoshino N; Kanekiyo M; Hagiwara Y; Okamura T; Someya K; Matsuo K; Ami Y; Sato S; Yamamoto N; Honda M
Scand J Immunol; 2008 Nov; 68(5):476-83. PubMed ID: 18803609
[TBL] [Abstract][Full Text] [Related]
32. Clinical development of Modified Vaccinia virus Ankara vaccines.
Gilbert SC
Vaccine; 2013 Sep; 31(39):4241-6. PubMed ID: 23523410
[TBL] [Abstract][Full Text] [Related]
33. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.
Seaman MS; Wilck MB; Baden LR; Walsh SR; Grandpre LE; Devoy C; Giri A; Noble LC; Kleinjan JA; Stevenson KE; Kim HT; Dolin R
J Infect Dis; 2010 May; 201(9):1353-60. PubMed ID: 20350190
[TBL] [Abstract][Full Text] [Related]
34. The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response.
Brandt T; Heck MC; Vijaysri S; Jentarra GM; Cameron JM; Jacobs BL
Virology; 2005 Mar; 333(2):263-70. PubMed ID: 15721360
[TBL] [Abstract][Full Text] [Related]
35. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
Abdalrhman I; Gurt I; Katz E
Vaccine; 2006 May; 24(19):4152-60. PubMed ID: 16603280
[TBL] [Abstract][Full Text] [Related]
36. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.
Earl PL; Americo JL; Wyatt LS; Espenshade O; Bassler J; Gong K; Lin S; Peters E; Rhodes L; Spano YE; Silvera PM; Moss B
Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10889-94. PubMed ID: 18678911
[TBL] [Abstract][Full Text] [Related]
37. [Primary vaccination against smallpox after preliminary vaccination with the attenuated vaccinia virus strain MVA and the use of a new "vaccination stamp"].
Stickl H; Hochstein-Mintzel V; Huber HC
Munch Med Wochenschr; 1973 Aug; 115(35):1471-3. PubMed ID: 4740817
[No Abstract] [Full Text] [Related]
38. Comparative efficacy of replicating smallpox vaccine strains in a murine challenge model.
Phelps A; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2005 May; 23(27):3500-7. PubMed ID: 15855008
[TBL] [Abstract][Full Text] [Related]
39. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination.
Vijaysri S; Jentarra G; Heck MC; Mercer AA; McInnes CJ; Jacobs BL
Vaccine; 2008 Jan; 26(5):664-76. PubMed ID: 18096276
[TBL] [Abstract][Full Text] [Related]
40. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax.
Midgley CM; Putz MM; Weber JN; Smith GL
J Gen Virol; 2008 Dec; 89(Pt 12):2992-2997. PubMed ID: 19008384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]